Navigation Links
Repligen in Medical News

Repligen Licenses Patent Rights for Treatment of Bipolar Disorder

...WALTHAM, Mass., March 31 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...rogram of any private, U.S. psychiatric hospital. repligen is developing RG2417, an oral formulation of uridi... Herlihy, President and Chief Executive Officer of repligen Corporation. "Treatment of the symptoms of bipola...

Repligen Announces ISO 9001:2000 Certification

... WALTHAM, Mass., Feb. 12 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ), a global leader in ...lated services underlying its Protein A business. repligen has supplied Protein A products to the biopharmace...ent and Chief Executive Officer of Repligen. repligen is the world's leading supplier of recombinant Pro...

Repligen Reports Second Quarter Fiscal Year 2009 Financial Results

... WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported result... Herlihy, President and Chief Executive Officer of repligen Corporation. "As of September 30th, we had $65 mil...cologic, toxicologic and pharmacodynamic profiles. repligen announced receipt of a $1 million research grant f...

Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder

... WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ...d relapse remain common clinical problems. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST

... WALTHAM, Mass., Oct. 30 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... be accessed at http://www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Compound Reverses Huntington's Symptoms in Mice

...published this week in the early edition of the Proceedings of the National Academy of Sciences . The study received funding from Massachusetts-based repligen Corp., which holds several patent applications related to HDAC (histone deacetylase) inhibitors, a class of agents that include HDACi 4b. Other HDA...

Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors

... WALTHAM, Mass., July 1 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "Fred's expertise and relationships w...es and is an inventor on numerous patents. About repligen Corporation ...

Repligen Announces Share Repurchase Program

... WALTHAM, Mass., June 18 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today announced that ...,000 shares of its common stock. Under the program repligen may repurchase shares from time to time at prevail... Herlihy, President and Chief Executive Officer of repligen Corporation. "Our strong financial position will a...

Repligen Announces Conference Call to Update Orencia(R) Lawsuit

... be accessed at http://www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...lings with the Securities and Exchange Commission. repligen assumes no obligation to update any forward-lookin...

Repligen Elects Earl Henry, M.D. to the Board of Directors

... WALTHAM, Mass., Dec. 13 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "Earl's strategic guidance and relati...rovider of clinical outsourcing solutions. About repligen Corporation ...
Repligen in Medical Technology

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

...Schimmel has also been the co-founder or founding director of numerous successful biotechnology companies, including Sirtris Pharmaceuticals, Alnylam, repligen Corporation, Alkermes, Inc., Momenta Pharmaceuticals and Cubist Pharmaceuticals, which were taken public on the NASDAQ and are well established as com...

Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer

...ing drugs to treat inherited and acquired energy impairment diseases. Dr. Rioux' three-decade career includes industry experience at companies such as repligen Corp., Arrow International, Variagenics, Inc., Biogen and GRP (Groupement de Recherche en Pharmacologie). He previously was a researcher in Clinical R...

Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder

... WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today announced that ...ill be the Principal Investigator of this study. repligen previously reported positive initial results from ...d over $200 million in funding since 1989. About repligen Corporation ...

Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging

...WALTHAM, Mass., April 16 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "We expect to complete patient enroll...s year and, if successful, file an NDA in 2009." repligen is currently conducting a Phase 3 clinical trial t...

Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging

...WALTHAM, Mass., March 26 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "There are approximately 150,000 panc...t could benefit from enhancement with secretin." repligen previously conducted a multi-center, baseline-cont...

Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder

... WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today announced posit... Herlihy, President and Chief Executive Officer of repligen Corporation. "The results of this study support fu...ed over $200 million in funding since 1989. About repligen Corporation ...

Repligen Reports Positive Phase 2 Clinical Trial Results of Secretin for MRI Imaging of the Pancreas

... of Orphan Products Development of the FDA granted repligen orphan drug designation for RG1068, synthetic huma...of the pancreas. Orphan drug designation qualifies repligen for seven years of exclusive marketing rights in t...or RG1068 for MRI imaging of the pancreas. About repligen Corporation ...
Repligen in Biological Technology

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

... WALTHAM, Mass., Aug. 6 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported resul... Herlihy, President and Chief Executive Officer of repligen Corporation. "Our financial resources will allow ...ge in Bipolar Disorder scale (CGI-BP-C). In March, repligen exclusively licensed worldwide rights to a patent ...

Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results

... WALTHAM, Mass., July 30 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...e accessed at www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results

... WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported resul... Herlihy, President and Chief Executive Officer of repligen Corporation. "Over the next twelve months, we wil...DRS (p=0.01) and the CGI-BP-C (p=0.04). In March, repligen exclusively licensed worldwide rights to a patent ...

Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results

... WALTHAM, Mass., June 4 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that... be accessed at www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT

... WALTHAM, Mass., March 9 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...or 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Reports Third Quarter Fiscal Year 2009 Financial Results

... WALTHAM, Mass., Feb. 5 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported resul... Herlihy, President and Chief Executive Officer of repligen Corporation. "Our financial resources will allow ...s. Stock Repurchase Program In June 2008, repligen announced that its Board of Directors authorized t...

Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST

... WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...or 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results

... WALTHAM, Mass., Jan. 29 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...ay be accessed at www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST

... WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ...ed for 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT

...WALTHAM, Mass., Sept. 17 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ...ed for 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...
Repligen in Biological Dictionary

Affymetrix

...t news headlines at MainStreet.com Research AFFYMETRIX INC historical prices, historical volume, splits and dividends. ... Orexigen Therapeutics, repligen and Affymetrix lead small-cap volume in ... Affymetrix to Host Conference Call on July 22, 2009 to Announce Second Quarter 2009 Results ... Af...
Other Tags
(Date:12/26/2014)... (PRWEB) December 26, 2014 It is said ... great dress. Today, UWDress.com, the famous wedding dress supplier, ... launches a site-wide cocktail gown promotion. , UWDress.com’s navy ... collection, and they come in high fashion styles. Simple dresses ... depending on the occasion; they are specially designed for those ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
Other Contents